CalciMedica, Inc. Common Stock (CALC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CalciMedica, Inc. Common Stock (CALC) has a cash flow conversion efficiency ratio of 0.731x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.85 Million) by net assets ($-6.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of CalciMedica, Inc. Common Stock to measure how much of total assets are equity-financed.
CalciMedica, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how CalciMedica, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CALC cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CalciMedica, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CalciMedica, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Medadvisor Ltd
AU:MDR
|
5.093x |
|
Way 2 Vat Ltd
AU:W2V
|
-1.805x |
|
Hiap Huat Holdings Bhd
KLSE:0160
|
0.130x |
|
Euroland Corporate SA
PA:MLERO
|
N/A |
|
Silla Textile Co.Ltd
KQ:001000
|
0.016x |
|
Meta Epsi Tbk PT
JK:MTPS
|
0.244x |
|
Globe Textiles (India) Limited
NSE:GLOBE
|
-0.089x |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
0.385x |
Annual Cash Flow Conversion Efficiency for CalciMedica, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of CalciMedica, Inc. Common Stock from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see CALC market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.64 Million | $-21.18 Million | 3.189x | +317.31% |
| 2024-12-31 | $14.41 Million | $-21.15 Million | -1.467x | +53.48% |
| 2023-12-31 | $8.16 Million | $-25.73 Million | -3.154x | -347.72% |
| 2022-12-31 | $-9.23 Million | $-11.76 Million | 1.273x | +362.85% |
| 2021-12-31 | $65.02 Million | $-31.50 Million | -0.484x | -43.21% |
| 2020-12-31 | $94.79 Million | $-32.06 Million | -0.338x | +69.21% |
| 2019-12-31 | $28.41 Million | $-31.21 Million | -1.099x | +53.20% |
| 2018-12-31 | $12.02 Million | $-28.22 Million | -2.348x | -- |
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxi… Read more